Biomarcadores y genes relacionados con el desarrollo del glioblastoma en adultos
Palabras clave:
Glioblastoma, biomarcadores, glioma, sistema nervioso central.Resumen
El glioblastoma es un tumor del sistema nervioso central (SNC) perteneciente a la familia de los gliomas. Este tumor suele presentar una elevada resistencia a los tratamientos convencionales debido a su alta heterogeneidad celular; por ello, se ha optado por el uso de técnicas diagnósticas avanzadas capaces de aportar información relevante sobre el tumor, los tejidos adyacentes y los biomarcadores relacionados. Precisamente por su gran variabilidad, estos marcadores biológicos constituyen un foco de estudio esencial en los glioblastomas, ya que proporcionan información crucial para conocer el pronóstico y las posibles terapias para el paciente, resultando fundamentales para un abordaje integral de la neoplasia.
Descargas
Referencias
1. Gisina A, Kholodenko I, Kim Y, Abakumov M, Lupatov A, Yarygin K. Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. Int J Mol Sci. 2022; 23(22):14224. DOI: 10.3390/ijms232214224.
2. Massagué J, Ganesh K. Metastasis-Initiating Cells and Ecosystems. Cancer Discov. 2021; 11(4):971-94. DOI: 10.1158/2159-8290.CD-21-0010.
3. Venkataramani V, Yang Y, Schubert MC, Reyhan E, Tetzlaff SK, Wißmann N, et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022; 185(16):2899-917.e31. DOI: 10.1016/j.cell.2022.06.054.
4. Sathe A, Grimes SM, Lau BT, Chen J, Suarez C, Huang RJ, et al. Single-Cell Genomic Characterization Reveals the Cellular Reprogramming of the Gastric Tumor Microenvironment. Clin Cancer Res. 2020; 26(11):2640-53. DOI: 10.1158/1078-0432.CCR-19-3231.
5. Han H, Du A, Li J, Han H, Feng P, Zhu Y, et al. Transitioning from molecular methods to therapeutic methods: An in‑depth analysis of glioblastoma (Review). Oncol Rep. 2025; 53(4):48. DOI: 10.3892/or.2025.8881.
6. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-18. Neuro Oncol. 2021; 23(12 Suppl 2):iii1-iii105. DOI: 10.1093/neuonc/noab200.
7. Karipidis K, Baaken D, Loney T, Blettner M, Brzozek C, Elwood M, et al. The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A systematic review of human observational studies - Part I: Most researched outcomes. Environ Int. 2024; 191:108983. doi: 10.1016/j.envint.2024.108983.
8. Ungan G, Pons-Escoda A, Ulinic D, Arús C, Ortega-Martorell S, Olier I, et al. Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous. NMR Biomed. 2024, 37(4):e5095. DOI: 10.1002/nbm.5095.
9. Yi GZ, Zhang HY, Que TS, Qu SQ, Li ZY, Qi ST, et al. Identification of the clinical and genetic characteristics of gliomas with gene fusions by integrated genomic and transcriptomic analysis. Eur J Med Res. 2025; 30(1):49. DOI:: 10.1186/s40001-025-02306-y.
10. Thornton ZA, Andrews LJ, Zhao H, Zheng J, Paternoster L, Robinson JW, et al. Brain multi-omic Mendelian randomisation to identify novel drug targets for gliomagenesis. Hum Mol Genet. 2025; 34(2):178-92. DOI: 10.1093/hmg/ddae168.
11. Shen Y, Thng DKH, Wong ALA, Toh TB. Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review. Exp Hematol Oncol. 2024; 13(1):40. DOI:10.1186/s40164-024-00512-8.
12. Chen W, Wang Y, Zhao B, Liu P, Liu L, Wang Y, et al. Optimal Therapies for Recurrent Glioblastoma: A Bayesian Network Meta-Analysis. Front Oncol. 2021; 11:641878. DOI: 10.3389/fonc.2021.641878.
13. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-51. DOI: 10.1093/neuonc/noab106.
14. Alorfi NM, Ashour AM, Alharbi AS, Alshehri FS. Targeting inflammation in glioblastoma: An updated review from pathophysiology to novel therapeutic approaches. Medicine (Baltimore). 2024; 103(21):e38245. DOI: 10.1097/MD.0000000000038245.
15. Wu Q, Berglund AE, Etame AB. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma. Int J Mol Sci. 2021 22(15):8324. DOI: 10.3390/ijms22158324.
16. Gilard V, Tebani A, Dabaj I, Laquerrière A, Fontanilles M, Derrey S, et al. Diagnosis and Management of Glioblastoma: A Comprehensive Perspective. J Pers Med. 2021; 11(4):258. DOI:10.3390/jpm11040258.
17. Mikkelsen VE, Solheim O, Salvesen Ø, Torp SH. The histological representativeness of glioblastoma tissue samples. Acta Neurochir (Wien). 2021; 163(7):1911-20. doi: 10.1007/s00701-020-04608-y.
18. Bruhn H, Tavelin B, Rosenlund L, Henriksson R. Do presenting symptoms predict treatment decisions and survival in glioblastoma? Real-world data from 1458 patients in the Swedish brain tumor registry. Neurooncol Pract. 2024; 11(5):652-9. DOI: 10.1093/nop/npae036.
19. Mrowczynski OD, Yang AL, Liao J, Rizk E. The Potential of Glioblastoma Patient Symptoms to Diagnose and Predict Survival. Cureus. 2021; 13(7):e16675. DOI: 10.7759/cureus.16675.
20. Wang ZL, Zhang CB, Liu YQ, Wang Z, Jiang T. Peripheral blood test provides a practical method for glioma evaluation and prognosis prediction. CNS Neurosci Ther. 2019; 25(8):876-83. DOI: 10.1111/cns.13120.
21. Lassman AB, Wen PY, van den Bent MJ, Plotkin SR, Walenkamp AME, Green AL, et al. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clin Cancer Res. 2022; 28(3):452-60. DOI:: 10.1158/1078-0432.CCR-21-2225.
22. Bruhn H, Blystad I, Milos P, Malmström A, Dahle C, Vrethem M, et al. Initial cognitive impairment predicts shorter survival of patients with glioblastoma. Acta Neurol Scand. 2022; 145(1):94-101. DOI:10.1111/ane.13529.
23. Bernstock JD, Gary SE, Klinger N, Valdes PA, Ibn Essayed W, Olsen HE, et al. Standard clinical approaches and emerging modalities for glioblastoma imaging. Neurooncol Adv. 2022; 4(1):vdac080. DOI: 10.1093/noajnl/vdac080.
24. Ye Z, Gary SE, Sun P, Mustafi SM, Glenn GR, Yeh FC, et al. The impact of edema and fiber crossing on diffusion MRI metrics assessed in an ex vivo nerve phantom: Multi-tensor model vs. diffusion orientation distribution function. NMR Biomed. 2021; 34(1):e4414. DOI: 10.1002/nbm.4414.
25. Zukotynski KA, Vajapeyam S, Fahey FH, Kocak M, Brown D, Ricci KI, Onar-Thomas A, et al. Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2017; 58(8):1264-9. DOI: 10.2967/jnumed.116.185389.
26. Henderson F, Abdullah KG, Verma R, Brem S. Tractography and the connectome in neurosurgical treatment of gliomas: the premise, the progress, and the potential. Neurosurg Focus. 2020; 48(2):E6. DOI: 10.3171/2019.11.FOCUS19785.
27. Azad TD, Duffau H. Limitations of functional neuroimaging for patient selection and surgical planning in glioma surgery. Neurosurg Focus. 2020; 48(2):E12. DOI: 10.3171/2019.11.FOCUS19769.
28. Balana C, Castañer S, Carrato C, Moran T, Lopez-Paradís A, Domenech M, et al. Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics. Front Neurol. 2022; 13:865171. DOI: 10.3389/fneur.2022.865171.
29. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021 18(5):297-312. DOI: 10.1038/s41571-020-00457-x.
30. Gatto L, Franceschi E, Di Nunno V, Tosoni A, Lodi R, Brandes AA. Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. Oncologist. 2021; 26(10):865-78. DOI: 10.1002/onco.13858.
31. Thenuwara G, Curtin J, Tian F. Advances in Diagnostic Tools and Therapeutic Approaches for Gliomas: A Comprehensive Review. Sensors (Basel). 2023; 23(24):9842. doi: 10.3390/s23249842.
32. Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022; 23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7.
33. McNamara C, Mankad K, Thust S, Dixon L, Limback-Stanic C, D’Arco F, et al. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology. 2022; 64(10):1919-50. DOI: 10.1007/s00234-022-03008-6.
34. Nguyen N, Redfield J, Ballo M, Michael M, Sorenson J, Dibaba D, et al. Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. CNS Oncol. 2021; 10(3):CNS74. DOI: 10.2217/cns-2021-0002.
35. Patil VM, Menon N, Chatterjee A, Tonse R, Choudhari A, Mahajan A, et al. Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial. EClinicalMedicine. 2022; 49:101449. doi: 10.1016/j.eclinm.2022.101449.
36. Chiu FY, Yen Y. Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives. Biomark Res. 2023; 11(1):35. DOI: 10.1186/s40364-023-00476-7.
37. Li YP, Liu Y, Xiao LM, Chen LK, Tao EX, Zeng EM, et al. Induction of cancer cell stemness in glioma through glycolysis and the long noncoding RNA HULC-activated FOXM1/AGR2/HIF-1α axis. Lab Invest. 2022; 102(7):691-701. doi: 10.1038/s41374-021-00664-9.
38. Adilay HU, Evran S, Katar S, Ozdemir A, Kayhan A, Avcikurt AS, et al. AGR2 Gene Expression in Glioblastoma: A Novel Molecular Potential Target for Diagnosis and Treatment. Turk Neurosurg. 2023; 33(2):265-71. DOI: 10.5137/1019-5149.JTN.37436-21.2.
39. Chen X, Liu J, Li Y, Zeng Y, Wang F, Cheng Z, et al. IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma. Nat Commun. 2023; 14(1):6781. DOI: 10.1038/s41467-023-42545-3.
40. Senhaji N, Squalli Houssaini A, Lamrabet S, Louati S, Bennis S. Molecular and Circulating Biomarkers in Patients with Glioblastoma. Int J Mol Sci. 2022; 23(13):7474. DOI: 10.3390/ijms23137474.
41. Ashkan K, Baig Mirza A, Soumpasis C, Syrris C, Kalaitzoglou D, Sharma C, et al. MGMT Promoter Methylation: Prognostication beyond Treatment Response. J Pers Med. 2023; 13(6):999. DOI:10.3390/jpm13060999.
42. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059.
43. Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, et al. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 2022; 24(12):2035-62. DOI: 10.1093/neuonc/noac204.
44. Wu Y, Zhou J, Zhang J, Tang Z, Chen X, Huang L, et al. Pertinence of glioma and single nucleotide polymorphism of TERT, CCDC26, CDKN2A/B and RTEL1 genes in glioma: a meta-analysis. Front Oncol. 2023; 13:1180099. DOI: 10.3389/fonc.2023.1180099.
45. Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers (Basel). 2022; 14(10):2412. DOI:10.3390/cancers14102412.
46. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013; 126(2):267-76. DOI:10.1007/s00401-013-1141-6.
47. Lin K, Gueble SE, Sundaram RK, Huseman ED, Bindra RS, Herzon SB. Mechanism-based design of agents that selectively target drug-resistant glioma. Science. 2022; 377(6605):502-11. DOI: 10.1126/science.abn7570.
48. Yue Q, Wang Z, Shen Y, Lan Y, Zhong X, Luo X, et al. Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention. Adv Sci (Weinh). 2024; 11(19):e2309290. DOI: 10.1002/advs.202309290.
49. Pratt D, Abdullaev Z, Papanicolau-Sengos A, Ketchum C, Panneer Selvam P, Chung HJ, et al. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13. Acta Neuropathol. 2022; 143(3):403-14. DOI:10.1007/s00401-022-02404-9.
50. Qin T, Mullan B, Ravindran R, Messinger D, Siada R, Cummings JR, et al. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization. Cell Rep. 2022; 38(2):110216. DOI: 10.1016/j.celrep.2021.110216.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Jerónimo Arbeláez-Posada
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
